PMGC Holdings is gaining in premarket trading after its subsidiary, Northstrive Biosciences, partnered with Yuva Biosciences to develop AI-powered therapies for cardiometabolic diseases. Yuva’s MitoNova platform will identify compounds that support mitochondrial health.
PMGC Stock Surges After Subsidiary Inks Deal With Yuva Biosciences To Develop AI Led Therapies
